JP2015518006A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518006A5
JP2015518006A5 JP2015514242A JP2015514242A JP2015518006A5 JP 2015518006 A5 JP2015518006 A5 JP 2015518006A5 JP 2015514242 A JP2015514242 A JP 2015514242A JP 2015514242 A JP2015514242 A JP 2015514242A JP 2015518006 A5 JP2015518006 A5 JP 2015518006A5
Authority
JP
Japan
Prior art keywords
human
allergic condition
composition
hydrochloride
performed via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015514242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518006A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/042925 external-priority patent/WO2013177594A2/en
Publication of JP2015518006A publication Critical patent/JP2015518006A/ja
Publication of JP2015518006A5 publication Critical patent/JP2015518006A5/ja
Pending legal-status Critical Current

Links

JP2015514242A 2012-05-25 2013-05-28 キシリトール系の抗粘膜組成物及び関連する方法並びに組成物 Pending JP2015518006A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651741P 2012-05-25 2012-05-25
US61/651,741 2012-05-25
PCT/US2013/042925 WO2013177594A2 (en) 2012-05-25 2013-05-28 Xylitol-based anti-mucosal compositions and related methods and compositions

Publications (2)

Publication Number Publication Date
JP2015518006A JP2015518006A (ja) 2015-06-25
JP2015518006A5 true JP2015518006A5 (enExample) 2017-03-23

Family

ID=49621806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514242A Pending JP2015518006A (ja) 2012-05-25 2013-05-28 キシリトール系の抗粘膜組成物及び関連する方法並びに組成物

Country Status (13)

Country Link
US (3) US8709508B2 (enExample)
EP (1) EP2854781A4 (enExample)
JP (1) JP2015518006A (enExample)
KR (1) KR20150011807A (enExample)
CN (1) CN104334164A (enExample)
AU (1) AU2013266067B2 (enExample)
BR (1) BR112014029442A2 (enExample)
CA (1) CA2870158C (enExample)
IL (1) IL235875A (enExample)
MX (1) MX2014013998A (enExample)
RU (1) RU2607892C2 (enExample)
WO (1) WO2013177594A2 (enExample)
ZA (1) ZA201408594B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
EP2854781A4 (en) 2012-05-25 2016-04-13 Xlear Inc XYLITOL-BASED ANTIMUKOSAL COMPOSITIONS AND ASSOCIATED METHODS AND COMPOSITIONS
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) * 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
JP2017505348A (ja) 2014-02-10 2017-02-16 パタラ ファーマ リミテッド ライアビリティ カンパニー 肺疾患治療のための肥満細胞安定剤
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US20180008598A1 (en) * 2016-07-07 2018-01-11 Xlear, Inc. Antibacterial nasal compositions and related methods
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US11602541B2 (en) 2020-04-24 2023-03-14 Joseph Scivoletto Nasal spray composition
WO2022140795A2 (en) * 2020-12-23 2022-06-30 Spotlight Therapeutics Nucleic acid binding protein formulations and uses thereof
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
CN116211884B (zh) * 2023-02-16 2024-05-17 海孵(海南自贸区)医疗科技有限责任公司 一种鼻腔喷雾剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01172324A (ja) * 1987-12-15 1989-07-07 Armour Internatl Co コレスチラミン組成物及びその製造法
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
IL131492A0 (en) * 1997-04-30 2001-01-28 Warner Lambert Co Topical nasal antiinflammatory compositions
US6054143A (en) * 1998-03-24 2000-04-25 Jones; Alonzo H. Xylitol delivery
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
MXPA06001776A (es) * 2003-08-15 2007-09-07 Qlt Usa Inc Sistema de suministro de farmaco transmucosal biocorrosivo, adhesivo.
US20060034947A1 (en) 2004-06-02 2006-02-16 Burr James B Erythritol compositions for nasopharynx cleansing
PL2486942T3 (pl) * 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
GB0426068D0 (en) * 2004-11-29 2004-12-29 Passion For Life Healthcare Lt Composition with bacteria blocking action
US20060120967A1 (en) * 2004-12-07 2006-06-08 Qpharma, Llc Solution forms of cyclodextrins for nasal or throat delivery of essential oils
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
US20070286812A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US20070286813A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US20100099650A1 (en) * 2006-10-10 2010-04-22 Knauer Kent A Nasal spray composition and method for treating rhinitis, sinusitis or both
WO2010078419A2 (en) * 2008-12-31 2010-07-08 Bzmi, Llc Herbal-based nasal solution and method of use thereof
DE202010012255U1 (de) * 2010-09-07 2010-11-18 Krewel Meuselbach Gmbh Nasenspray
EP2854781A4 (en) 2012-05-25 2016-04-13 Xlear Inc XYLITOL-BASED ANTIMUKOSAL COMPOSITIONS AND ASSOCIATED METHODS AND COMPOSITIONS

Similar Documents

Publication Publication Date Title
CA2870158C (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EA201491844A1 (ru) Распыляющие спрей эжекторные механизмы и устройства, выполненные с изоляцией и возможностью управляемого создания заряда на каплях, и нанесение малообъемных доз офтальмологических средств
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
MX2015015589A (es) Composiciones y metodos para el suministro de agentes activos hidrófobos.
JP2013534527A5 (enExample)
HRP20171739T1 (hr) Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
WO2010024956A3 (en) Antihistamine and antihistamine-like nasal application, products, and method
CO6400184A2 (es) Formulaciones galénicas de compuestos orgánicos
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
JP2016525548A5 (enExample)
ATE507818T1 (de) Orale verabreichung eines calcitonins
BR112014005538A2 (pt) composições aquosas compreendendo arbecacina
DOP2015000071A (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112013019876A2 (pt) formulação farmacêutica, uso da formulação farmacêutica, frasco e kit
JP2014530847A5 (enExample)
BR112015030341A2 (pt) formulações de nanoparticulado e processo para prepará-las, composição farmacêutica e uso de composto ou seu sal farmaceuticamente aceitável e estabilizante de superfície
WO2014011949A3 (en) Neuroprotective cb2 receptor agonists
MX380536B (es) Composicion y metodo para tratar la enfermedad de chagas.
BR112016011999A2 (pt) Derivados de amida para agonista de gpr119
BR112013029790A2 (pt) composição farmacêutica compreendendo cetoprofeno
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo